Mandate

Vinge advises Concordia Bus in connection with new share issue and refinancing

September 08, 2009

Vinge has advised Concordia Bus in connection with the implementation of a rights issue subject to pre-emption rights for the existing shareholders and the exchange of the company’s existing senior notes in the amount of EUR 130 million for new senior notes. In connection with the rights issue, all of the company’s outstanding preference shares were redeemed. The new issue will generate just over SEK 800 million for the company.

Concordia Bus is one of Europe’s ten largest public transportation groups and the Nordic region’s leading bus transportation group. The group has approximately 7,000 employees and a turnover of approximately SEK 5.5 billion.

The Vinge team consisted of Ola Sandersson, Maria-Pia Midenbäck Hope, Bo Adrianzon, Mattias Schömer, Maria Doeser, Dain Nevonen, Nils-Taro Lock, Elin Hjort and Christian Granqvist.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024